Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
The program, which began Dec. 6 in the wake of ongoing H5N1 outbreaks at dairy farms, now includes 28 states covering 65% of the country's milk production. Other public health news is on chronic ...
RSV infections in children younger than 5 years in primary care are associated with substantial symptomatology, health-care ...
Barré for every million doses given.
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback